Manchester Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Manchester Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,850	Closed	-$115K	–	1292
2025 Q2	$115K	Hold	9,850	–	–	0.02%	429
2025 Q1	$73.2K	Hold	9,850	–	–	0.01%	480
2024 Q4	$59.1K	Hold	9,850	–	–	0.01%	516
2024 Q3	$50.4K	Hold	9,850	–	–	0.01%	539
2024 Q2	$35.7K	Hold	9,850	–	–	﹤0.01%	561
2024 Q1	$31.6K	Buy	+9,850	New	+$38.1K	﹤0.01%	513
2023 Q4	–	Sell	-9,850	Closed	-$53.7K	–	1004
2023 Q3	$53.7K	Hold	9,850	–	–	0.01%	405
2023 Q2	$66.1K	Hold	9,850	–	–	0.01%	387
2023 Q1	$87K	Buy	+9,850	New	+$86.8K	0.01%	373
2022 Q4	–	Sell	-7,795	Closed	-$56K	–	994
2022 Q3	$56K	Buy	7,795 +4,695	+151%	+$44.2K	0.01%	352
2022 Q2	$25K	Hold	3,100	–	–	﹤0.01%	396
2022 Q1	$43K	Buy	+3,100	New	+$48.7K	0.01%	407
2021 Q4	–	Sell	-2,820	Closed	-$96K	–	999
2021 Q3	$96K	Buy	2,820 +2,620	+1,310%	+$94.8K	0.01%	366
2021 Q2	$8K	Hold	200	–	–	﹤0.01%	510
2021 Q1	$8K	Buy	+200	New	+$10.8K	﹤0.01%	493

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Manchester Capital Management's ADPT Position: Q3 2025 in Review

Manchester Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2025, closing a stake of 9,850 shares — an estimated $115K sold.

Manchester Capital Management first reported a position in ADPT in Q1 2021 and held it in 15 quarters. The position peaked at $115K in Q2 2025. 271 funds tracked by Wall St. Rank hold ADPT as of Q3 2025.

Manchester Capital Management reported no remaining Adaptive Biotechnologies position as of Q3 2025 after selling out during the quarter.
Manchester Capital Management sold 9,850 Adaptive Biotechnologies shares in Q3 2025, an estimated $115K.
Manchester Capital Management first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 15 quarters.
Manchester Capital Management's Adaptive Biotechnologies position peaked at $115K in Q2 2025.
271 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2025.

Based on Manchester Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.